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Abstract
Background: Peritoneal dissemination often develops in gastric cancer. Tumor-associated macrophages (TAMs) are
present in the peritoneal cavity of gastric cancer patients with peritoneal dissemination, facilitating tumor
progression. However, the mechanism by which macrophages differentiate into tumor-associated macrophages in
the peritoneal cavity is not well understood. In this study, the interplay between gastric cancer-derived extracellular
vesicles (EVs) and macrophages was investigated.
Methods: The association between macrophages and EVs in peritoneal ascitic fluid of gastric cancer patients, or
from gastric cancer cell lines was examined, and their roles in differentiation of macrophages and potentiation of
the malignancy of gastric cancer were further explored.
Results: Immunofluorescent assays of the ascitic fluid showed that M2 macrophages were predominant along with
the cancer cells in the peritoneal cavity. EVs purified from gastric cancer cells, as well as malignant ascitic fluid,
differentiated peripheral blood mononuclear cell-derived macrophages into the M2-like phenotype, which was
demonstrated by their morphology and expression of CD163/206. The macrophages differentiated by gastric
cancer-derived EVs promoted the migration ability of gastric cancer cells, and the EVs carried STAT3 protein.
Conclusion: EVs derived from gastric cancer play a role by affecting macrophage phenotypes, suggesting that this
may be a part of the underlying mechanism that forms the intraperitoneal cancer microenvironment.
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Background
Gastric cancer (GC) is one of the most common cancers
and the third leading cause of cancer-related death in
the world [1]. Peritoneal dissemination is one of the
most common metastatic patterns of GC [2], and it re-
sults in a poor prognosis, but its underlying mechanism
remains unclear. In the tumor microenvironment
(TME), co-stimulation between normal cells and cancer
cells is reported to be important in promoting malig-
nancy [3, 4]. Macrophages physiologically play roles in
dead cell destruction, vessel formation, and inflamma-
tion induction [5], and they are also one of the key
players even in the TME, where they are called tumor-
associated macrophages (TAMs). Macrophages are
classified into dichotomous phenotypes: the classical M1
type and the alternative M2 type macrophages. M1 type
macrophages have a role in anti-tumor immunity and
the inflammatory response. On the other hand, M2 type
macrophages are involved in the anti-inflammatory re-
sponse, wound healing, and pro-tumorigenic properties.
TAMs are generally considered to more closely resemble
the M2-type and thereby modulate the pro-tumor
microenvironment [6]. Thus, TAMs in tumor tissues
have been shown to be prognostic biomarkers for vari-
ous cancers [7]. In addition, targeting TAMs has been
investigated in clinical studies [7–9].
Extracellular vesicles (EVs) play an essential role in inter-
cellular communication between tumor and surrounding
stromal cells or even between tumor and distant cells. In
general, EVs, including exosomes and microvesicles, are
small membrane vesicles that contain various carriers, such
as microRNAs (miRNAs), messenger RNAs, and proteins
[10–13]; they can be released from various types of cells
and function in communication between cells through
transferring their contents [14, 15]. Accumulating evidence
has shown that EVs secreted from cancer cells affect sur-
rounding cells and even cells at distal sites, thereby enabling
the development of a TME that promotes tumor growth
[16–19]. For instance, tumor exosomal integrins could de-
termine organotrophic metastasis [20], and EVs secreted
from GC also deliver EGFR, which could induce liver me-
tastasis [21]. Furthermore, Wu et al. reported that EVs from
GC activate macrophages to promote cancer progression
[22]. These reports suggested a critical pro-tumor role of
cancer-derived EVs in the TME [23, 24].
Recent studies by us and other investigators have
shown that macrophages in the peritoneal cavity, espe-
cially M2-type macrophages, could contribute to progres-
sion of GC with peritoneal dissemination [25, 26].
However, the mechanisms of how macrophages change
their phenotype in the microenvironment remain unclear.
We hypothesized that EVs are secreted from GC cells in
the peritoneal cavity, and they might affect the phenotype
of macrophages to promote dissemination.
In this study, the interplay between GC-derived EVs
and macrophages was investigated, and the background
mechanism involved in the formation of intraperitoneal
cancer microenvironment was evaluated.
Methods
Cell culture
The GC cell line, GCIY, was purchased from RIKEN
(Saitama, Japan) and cultured in MEME (Sigma-Aldrich,
St. Louis, MO, USA) supplemented with 15% fetal
bovine serum (FBS) and 1% penicillin/streptomycin
(Sigma-Aldrich), and other GC lines, MKN7 and
MKN45, were purchased from the Japanese Collection
of Research Bioresources cell bank and cultured in
RPMI1640 (Sigma-Aldrich) supplemented with 10% FBS
and 1% penicillin/streptomycin. The human mesothelial
cell line (MeT-5A) was purchased from the American
Type Culture Collection (ATCC, Manassas, VA, USA)
and cultured in McCoy’s 5A medium (Thermo Fisher
Scientific, Tokyo, Japan) supplemented with 10% FBS
and 1% penicillin/streptomycin. All cells were main-
tained at 37 °C in a humidified atmosphere with 5%
CO2. We purchased the cell lines used in the experi-
ments directly from the authorized distributors and con-
firmed that all cell lines were uncontaminated in the
public databases. Additional information on cell lines is
provided in the Supplementary Table.
Preparation of EVs
EVs were isolated by ultracentrifugation according to
the methods previously reported [27]. Briefly, cells were
washed with PBS twice and cultured in the medium with
exosome-depleted fetal bovine serum (after overnight
centrifugation at 100,000 g) for 48 h. The conditioned
medium (CM) was collected and centrifuged at 2000 g
for 10 min, and the supernatant was filtered through a
0.22-um filter (Millipore®, Merck, Tokyo, Japan). The
CM was then ultracentrifuged at 100,000 g for 70 min,
and the pellet was finally washed by PBS and centrifuged
at 100,000 g for 70 min.
To prepare EVs from clinical samples, peritoneal
washings or ascitic fluid was collected from patients who
gave their informed consent to participate in the study
[28, 29]. Peritoneal washings or ascitic fluid were
obtained during operation for the purpose of cytology.
Ascites, if present, is aspirated; if not, 100 ~ 200mL of
normal saline is instilled into the Douglas pouch, gently
stirred, and then aspirated as peritoneal washings. Half
of it was subjected to pathological cytology and the other
half was stored at − 80 °C for the study. Those used in
this study were selected retrospectively in consideration
of stock status and clinical stages. The clinicopathologi-
cal data were obtained from the medical records, and
the cancers were staged in accordance with the Japanese
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Classification of Gastric Carcinoma: 3rd English edition
[30]. After thawing the frozen samples, first, peritoneal
washings or ascitic fluid was centrifuged at 300 g for 5
min. The supernatant was again centrifuged at 2000 g
for 10 min to remove dead cells and debris. The super-
natant was centrifuged at 10,000 g for 30 min to remove
large EVs. Finally, the supernatant was ultracentrifuged
at 100,000 g for 70 min, and the pellet was washed by
PBS and centrifuged at 100,000 g for 70 min. After the
EVs were resuspended in PBS, the putative protein
amount was measured by Micro BCA Protein Assay
(Thermo Fisher Scientific) according to the manufacturer’s
protocol, and vesicle size was measured by Zetasizer
(Malvern Panalytical Ltd., Malvern, United Kingdom).
Transmission electron microscopy (TEM)
Briefly, 10 μl of a suspension of EVs were placed on a
carbon coated copper grid for 15 min, and excess
suspension liquid was removed. The samples were
negatively stained with 2% uranyl acetate solution for 2
min. After air drying, the samples were visualized using
an H-7650 transmission electron microscope (Hitachi
High-technologies, Tokyo, Japan) in the Central Research
Laboratory, Okayama University Medical School.
Monocyte and macrophage preparation from peripheral
blood mononuclear cells (PBMCs)
PBMCs were collected from whole blood of healthy donors.
PBMCs were obtained from buffy coats by Ficoll-Paque (GE
Healthcare Biosciences, Piscataway, NJ; catalog 17–1440-02)
density gradient centrifugation at 400 g at 20 °C for 40min
to separate blood constituent parts. After purified cells were
washed with PBS, CD14+ monocytes were isolated using
the Pan Monocyte Isolation kit (Miltenyl Biotec, San Diego,
CA; catalog 130–096-537) followed by separation using
magnetic LS columns (Miltenyl Biotec; catalog 130–042-
401), according to the manufacturer’s protocol.
Macrophages were differentiated from these monocytes
according to the previous reports [31, 32]. The monocytes
were cultured in RPMI1640 with either GM-CSF at 20 ng/
ml (named M0-GM) or M-CSF at 20 ng/ml (named M0-
M) for 5 days. M0-GM macrophages were then stimulated
by LPS (20 ng / ml) and IFN-γ (20 ng / ml) for 4 days to
polarize into CD80+ / CD86+ (M1) macrophages. On the
other hand, M0-M macrophages were stimulated by IL-4
(20 ng / ml) and IL-13 (20 ng / ml) for 4 days to polarize
into CD163+ or CD206+ (M2) macrophages (Fig. S3A-C).
M0-GM or M0-M macrophages were stimulated by EVs
(20 μg / ml) for 4 days to assess the effects of EVs.
EVs uptake
CD14+ cells were purified from PBMCs. Collected EVs
from each cell line were labelled with the PKH26 Red
Fluorescent Cell Linker Mini Kit (Sigma-Aldrich) for
visualization according to the manufacturer’s protocol.
EVs were incubated with 2 μM of PKH26 for 5 min and
washed twice. To remove excess dye, Exosome Spin
Columns (MW3000) (Thermo Fisher Scientific) were
used. PKH26-labeled EVs were used to confirm EV up-
take in monocytes or macrophages. Cells were incubated
with PKH26-labeled EVs purified from GCIY culture
medium (GCIY-EVs) and analyzed by fluorescence mi-
croscopy and flow cytometry.
Immunofluorescence staining
Malignant ascitic fluid or peritoneal washings were cen-
trifuged to collect cells, and the cells were resuspended
in RPMI-1640 supplemented with 10% FBS. The number
of viable cells was counted, and the cancer cells were la-
beled with GFP by infection with the cancer-imaging
virus OBP-401 at 1 multiplicity of infection for 24 h at
37 °C. Cancer cells were detected as GFP-positive cells
[33–35]. Macrophages were stained with PE or Alexa
Fluor 647-conjugated anti-human CD14 antibody (Bio-
Legend, San Diego, CA, USA) as a pan-macrophage
marker and PE-conjugated anti-human CD163 antibody
(BioLegend) as a marker of M2 macrophages, respect-
ively. The nucleus was stained with 4′, 6-diamidino-2-
phenylindole (DAPI). Stained cells were observed under
an inverted fluorescence microscope (IX71; Olympus,
Tokyo, Japan) equipped with the DP70 camera. The im-
ages were captured using the DP controller software
(Olympus). The imaging using OBP-401 was applied
only for Fig. 1 a and b.
Mouse peritoneal dissemination model
Female BALB/c (nu / nu) mice were purchased from
CLEA (Tokyo, Japan). Five million of each of the cancer
cells including GCIY, MKN7, and MKN45 were inocu-
lated into the peritoneal cavity (n = 5 / group, n = 15 in
total) when the mice were 6 weeks of age. Tumor
burdens were evaluated by an IVIS Spectrum system
(Caliper Life Sciences, Waltham, MA, USA) every week.
After the experiment, the mice were euthanized by car-
bon dioxide inhalation followed by cervical dislocation.
Flow cytometry
Collected cells were washed twice and suspended in PBS
with 2% FBS before staining. Cells were evaluated by
surface markers using directly-labeled primary monoclo-
nal antibody (mAb) CD80-PE / Cy7, CD86-APC, CD163-
PE, CD206-FITC, and the appropriate isotype-controls for
each antibody (BioLegend). After cells were stained for 30
min, they were washed twice and suspended in PBS. These
samples were subjected to BD FACS Lyric (BD Biosci-
ences), and the data were analyzed using FlowJo software
(Becton, Dickinson and Company, Ashland, OR, USA).
Viability was analyzed assay by the Annexin V-FITC Early
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Apoptosis Detection Kit (Cell signaling Technology)
according to the manufacturer’s protocol.
Western blot
Equivalent amounts of protein from whole-cell lysates or
EVs were loaded into each lane of SDS-polyacrylamide
gel and electrophoretically transferred to polyvinylidene
difluoride membranes (Hybond-P; GE Health Care,
Buckinghamshire, UK). Membranes were incubated in
Blocking One or Blocking One-P (Nacalai Tesque, Inc.,
Kyoto, Japan) for 30 min before being incubated in the
following primary antibodies overnight at 4 °C: anti-CD9
(Chemicon International Inc., Temecula, CA, USA),
anti-CD63 (BD Biosciences), anti-CD81 (BioLegend),
anti-signal transducer and activator of transcription 3
(STAT3; Cell Signaling Technology), anti-phosphorylated
STAT3 (p-STAT3; Cell Signaling Technology), anti-Akt
(Akt; Cell Signaling Technology), anti-phosphorylated Akt
(p-Akt; Cell Signaling Technology), and anti-β-actin anti-
body (Sigma-Aldrich). The membranes were subsequently
incubated with secondary antibodies for 60min at room
temperature. Peroxidase activity of secondary antibodies
was detected using ECL prime Western Blotting Detection
Reagent (GE Healthcare UK Ltd.) and visualized using an
Amersham Imager 600 (GE Healthcare UK Ltd.) accord-
ing to the manufacturer’s protocol.
Migration assay
The migration assay was performed using Transwell 24-
well plates with 8-μm-pore polyethylene terephthalate
(PET) track-etched membranes (CORNING). GC cells
were indirectly co-cultured with macrophages stimulated
by various EVs (ratio 1: 2) using Transwell 6-well plates
with 4-μm-pore PET track-etched membranes (CORN-
ING) for 48 h. Then, 1 × 105 cells of MKN7 were seeded
in the upper chamber with 500 μl of RPMI1640 containing
0.1% FBS. The lower chamber was filled with RPMI1640
containing 10% FBS. After incubation for 24 h at 37 °C,
migrating cells were fixed with 4% paraformaldehyde and
stained with 0.5% crystal violet. The number of cells on
Fig. 1 CD163-positive macrophages predominate in both peritoneal washings from a cytology-positive GC patient and malignant ascitic fluid. EVs
were contained in malignant ascitic fluid. a and b are immunofluorescent images of the same malignant ascitic fluid. a Cancer cells and
monocytes were imaged by the cancer-imaging virus OBP-401 (GFP) and anti-CD14 antibody (PE), respectively. Macrophages were present in
malignant ascitic fluid. b M2 macrophages were imaged by anti-CD163 antibody (PE). Scale bar: 100 μm. c Transmission electron microscope
image of EVs from MA. Scale bar: 500 nm. d Vesicle size measured by dynamic light scattering analyses. e Representative Western blot of cells
and EVs in MA to confirm the presence of EVs by exosome markers (CD9, CD63, CD81). Full-length blots / gels are presented in Fig. S5
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the lower surface of the upper chamber membrane in 5
random fields was counted using a bright field light
microscope.
ELISA for human IL-6
The IL-6 levels secreted by macrophages were deter-
mined using an enzyme-linked immunosorbent assay
(ELISA) kit (Human IL-6, catalog # D6050, R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s
instructions.
Statistical analysis
Unless otherwise stated, results are expressed as means
± S.D. Student’s t-test was used to compare continuous
data, and a P value less than 0.05 was considered signifi-
cant. All statistical analyses were conducted with EZR
(Saitama Medical Center, Jichi Medical University),
which is a graphical user interface for R (The R Founda-
tion for Statistical Computing, version 2.13.0).
Results
CD163 +macrophages and extracellular vesicles were
detected in cytology-positive peritoneal washings or
malignant ascitic fluid from gastric cancer patients
Since it has been reported that intraperitoneal macrophages
are preferentially differentiated into M2 macrophages in GC
patients, cellular components in peritoneal washings in a
case of a peritoneal cytology-positive GC patient were inves-
tigated. It was confirmed that numerous CD14+ cells existed
in the peritoneal cavity along with GFP-positive cancer cells
(Fig. 1a). When they were stained with anti-CD163 antibody,
abundant CD163+, M2-type, macrophages were present
(Fig. 1b). Such results let us to investigate how these intra-
peritoneal tumor-associated macrophages were skewed to
M2 types.
EVs were reported to function in the intercellular
communications, so we then attempted to extract EVs
from malignant ascites and peritoneal washings to verify
whether EVs were present in the peritoneal cavity. EVs
were purified from malignant ascitic fluid derived from
GC patients with cancer dissemination (Fig. 1d-f) or
peritoneal washings collected during surgery for a GC
patient (Fig. S1 A, B), indicating that a certain amount
of EVs existed in the peritoneal cavity in GC patients. It
was presumed that some of these EVs were derived from
GC cells, which prompted us to further investigate the
possible interaction of EVs derived from GC cells and
intraperitoneal macrophages.
EVs from GC cell lines sustained the viability of
monocytes and induced PD-L1 expression on these
surviving monocytes
Although macrophages differentiate from monocytes,
when and how macrophages were further differentiated
to M1 or M2 types in the peritoneal environment were
unknown. Therefore, the effect of EVs from GC cell
lines on macrophages was examined in vitro. To com-
pare the functionality of EVs between EVs from normal
cells and EVs from cancer cells, EVs were purified from
a normal mesothelial cell line (MeT-5A) and 3 GC cell
lines, GCIY, MKN7, and MKN45 (Fig. 2a-c, Fig. S2A-C).
These 3 GC cell lines were chosen from among the
available lines, because we have previously confirmed
that these cells displayed different aggressiveness in
terms of tumorigenesis. GCIY and MKN45 cells develop
peritoneal dissemination after peritoneal injections, but
MKN7 cells do not (Fig. S2D). In addition, GCIY cells
grow more aggressively than MKN45 cells (Fig. S2D).
Whether EVs affect CD14+ monocytes, precursors of
macrophages, was investigated first. More than 50% of
monocytes could take up EVs purified from GCIY cul-
ture medium (GCIY-EVs) in 48 h (Fig. 2d and Fig. S2E),
but, on the other hand, CD14-negative cells (mainly
lymphocytes) could not take up GCIY-EVs (Fig. S2F).
The viability assay and surface marker analysis for
monocytes treated with EVs demonstrated that mono-
cytes could sustain high viability with GCIY-EVs,
MNK45-EVs or MKN7-EVs, while about 80% of mono-
cytes died without the GC-derived EVs (Fig. 2e). Such
surviving monocytes highly expressed CD86, as well as
CD163 (Fig. 2f), with or without GC-derived EVs. The
expression of CD206 was found to be increased by
GCIY-EVs, but not by MET-5A-EVs, MKN-45-EVs or
MKN7-EVs (Fig. 2f). The expression of PD-L1 on the
surface of monocytes was found to be increased by
GCIY-EVs and MKN7-EVs (Fig. 2g).
GC cell-derived EVs (GC-EVs) affected monocytes to
increase the sustainability and expression of CD206 and
PD-L1, suggesting that GC-EVs might be associated with
skewing macrophage phenotype.
Macrophages derived from PBMCs were skewed to an
M2-like phenotype by GC-EVs, and these macrophages
promoted the malignancy of cancer cells by secreting IL-6
The effect of GC-EVs on cells at different stages in the
process of monocyte-macrophage differentiation was
further examined. Before the analysis, it was confirmed
that M1 or M2 macrophages could differentiate from
PBMC-derived CD14+ monocytes by GM-CSF or M-
CSF stimulation, in terms of morphology and surface
markers (Fig. S3A-C). Based on that, monocytes on day
5, just after GM-CSF or M-CSF treatment, were
regarded as immature macrophages and named M0-GM
or M0-M, respectively. The uptake of GC-EVs into day
5 macrophages (M0-GM or M0-M) was then checked
using PKH26-labeled EVs. The EVs were taken up by
both macrophages after incubation for only 3 h (Fig. 3a
and b). Next, M0-GM and M0-M macrophages were
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Fig. 2 Extracellular vesicles derived from GCIY (upper) and MeT-5A (lower). a Transmission electron microscope image of EVs. Scale bar: 500 nm. b
Vesicle size measured by dynamic light scattering analyses. c Representative Western blot of original cell lysates and EVs to confirm the presence
of EVs by exosome markers (CD9, CD63, CD81). Full-length blots / gels are presented in Fig. S6 and S7. d The uptake of GCIY-EVs into CD14-
positive cells (monocytes) was analyzed by flow cytometry. e-g Flow cytometry analysis for monocytes co-cultured with EVs for 48 h. N = 3, in
each samples. e The viability of monocytes treated with each EVs. f The positive rates of the markers on each monocyte. g PD-L1 expression on
each monocyte. (*: p < 0.05, NS: not significant, Student’s t-test)
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treated with GCIY-EVs for 4 days, and the surface markers
of these macrophages were observed. After the treatment
with GCIY-EVs, the macrophages expressed CD80 and
CD86 weakly and CD163 and CD206 strongly, regardless
of preconditioning with GM-CSF or M-CSF (Fig. 3c-e).
From the above results, it was found that GC-EVs pro-
moted the differentiation of macrophages into M2 type,
and we next examined whether the properties of
macrophages could be altered by the malignant charac-
ters of gastric cancer cells from which EVs were derived.
Although GCIY and MKN45 cells develop peritoneal
dissemination after peritoneal injections, GCIY cells
grow more aggressively than MKN45 cells. In contrast,
MKN7 cells could not develop peritoneal dissemination
(Fig. S2D). MKN7 cells were co-cultured with macro-
phages stimulated by GCIY-EVs, and their migratory
Fig. 3 PBMCs-derived macrophages that were polarized into M2 type by treatment with GCIY-EVs promoted malignancy of cancer cells via IL-6
secretion. a, b The uptake of EVs by day 5-macrophages is visualized. M0-GM Macrophages (a) and M0-M macrophages (b) were stained by
Calcein for the cytoplasm, and Hoechst for the nucleus. EVs were stained by PKH26 before co-culture. Magnification, × 200. bar: 100 μm. c
Protocol for differentiation of monocytes. d Morphology of M0-GM and M0-M macrophages. e Surface markers of macrophages treated with
GCIY-EVs. Upper figures are macrophages treated from M0-GM and lower are from M0-M. CD80 and CD86 were adopted as M1 markers, and
CD163 and CD206 as M2 markers. Scale Bar: 100 μm. f Migration assay of MKN7 cells co-cultured with M0-GM macrophages treated by EVs.
Control: Cancer cells only. M0-GM: Cancer cells co-cultured with untreated macrophages. M0-GM/MET-EVs: Cancer cells co-cultured with
macrophages treated with MET-5A cells-derived EVs. M0-GM/GC-EVs: Cancer cells co-cultured with macrophages treated with GCIY cell-derived
EVs. g Migration assay of MKN7 cells co-cultured with M0-M macrophages treated by EVs. h Concentration of IL-6 in the supernatant of
macrophages treated with each EV was analyzed by ELISA assay. (*: p < 0.05, NS: not significant, Student’s t-test)
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capacity was analyzed. These MKN7 cells were able to
migrate more than MKN7 cells co-cultured with either
macrophages without EV-treatment or those treated by
MeT-5A cell-derived EVs (Fig. 3f and g). Moreover, mac-
rophages treated by GCIY-EVs enhanced the migration
ability of MKN7 cells more than macrophages treated by
other GC-EVs (MKN7 or MKN45) (Fig. S3D).
Since it was reported that TAMs secrete IL-6 and pro-
mote malignancy of GC cells [25], whether macrophages
increase secretion of IL-6 by stimulation of GC-EVs was
then checked. In this assay, only M0-GM macrophages
were used, because mature macrophages polarized from
M0-M macrophages were unstable without cytokines or
EVs. M0-GM macrophages were treated by each EV for
4 days to prepare mature macrophages. Analysis of the
IL-6 level of the supernatant revealed that the macro-
phages treated by GC-EVs secreted more IL-6 than
other macrophages (Fig. 3h).
Based on the results that GC-EVs were associated with
skewing macrophages, and the resultant macrophages
further secreted IL-6 and affected the phenotypes of can-
cer cells, GC-EVs must be playing a role in aggravating
gastric cancer malignancy.
EVs from a highly metastatic gastric cancer cell line carry
STAT3, which was transferred into macrophages to
change their phenotype
STAT3 or Akt expression levels in GC cell lines and
EVs were examined. GCIY and MKN45, metastatic cell
lines, expressed high levels of STAT3. GCIY-EVs con-
tained more STAT3 than EVs from other GC cell lines.
On the other hand, MKN7, a non-metastatic cell line,
contained low levels of STAT3 and Akt (Fig. 4a and b).
After treatment by GCIY-EVs (20 μg/ml), GM-M0
macrophages increased their STAT3 levels, although
phosphorylated STAT3 levels were not elevated (Fig.
4c). STAT3 contained in GC-EVs might have a role in
polarizing macrophages.
EVs from malignant ascitic fluid affect macrophages,
causing them to polarize into M2 phenotype
Finally, whether EVs purified from clinical malignant as-
citic fluid from GC patients with peritoneal dissemin-
ation (malignant EVs) have an effect on macrophages
was examined. After GM-M0 or M-M0 macrophages
were treated by malignant EVs for 4 days, the macro-
phages changed their morphology into M2-like ones
(Fig. 5a), and the expression of CD163 was increased
(Fig. 5b). Moreover, whether EVs purified from periton-
eal washings or malignant ascitic fluid of GC patients
contained STAT3 or Akt was also evaluated. STAT3 was
detected in EVs from peritoneal washings of GC patients
with disseminated nodules, as well as EVs from malig-
nant ascitic fluid (Fig. 5c), while neither STAT3 nor Akt
could be detected in EVs from patients without dissem-
ination (Fig. 5d). These results suggested that STAT3
packed in EVs might be one of the mediators associated
with skewing macrophage phenotypes.
Discussion
In the present study, CD163+ M2 macrophages were
predominant in the peritoneal cavity of GC patients.
Since the underlying mechanism of preferential differen-
tiation of macrophages remains to be clarified, whether
EVs were secreted from GC cells and played a role in af-
fecting monocytes or macrophages to polarize them was
examined. EVs were isolated from the culture medium
of GC cells, as well as clinical malignant ascitic fluid.
Treatment with these EVs affected macrophages to make
them more sustainable and skewed into a CD163+ type.
Interestingly, the effect was observed regardless of
whether they were on the process from monocyte to M1
or M2 macrophages. In addition, STAT3 protein was
found to be carried in the EVs, indicating that STAT3 in
the EVs might be a mediator between GC cells and
monocytes/macrophages (Fig. S4).
Growing evidence suggests that the association be-
tween cancer-derived EVs and the tumor microenviron-
ment must play a crucial role in the progression of
various cancers. In the present study, monocytes treated
by GC-EVs survived more, and most of them expressed
CD163 on their surface, which might be one of the rea-
sons why CD163+ cells were predominant in malignant
ascitic fluid. Moreover, these monocytes were expressing
PD-L1.
PD-L1 on macrophages might bind to PD-1 on T cells
and suppress T cell-mediated cancer immunity, as
previously shown in glioblastoma [36]. In addition,
monocytes polarized to the M2 macrophage phenotype
upregulate PD-L1 and elaborate cytokines, such as
MCP-3 and CXCL1, which further enhance immune in-
filtration, the induction of angiogenesis, and the recruit-
ment of myeloid cells into the tumor microenvironment
[37, 38]. Therefore, these situations might be caused by
GC-derived EVs and contribute to maintaining the
immune-suppressive microenvironment in the peritoneal
cavity, thereby supporting further peritoneal spread of
GC.
In addition, macrophages co-cultured with GCIY-EVs
increased the migration ability of cancer cells. TAMs are
known to promote the malignant potential of cancer
cells, as previously reported [22, 25], consistent with the
present results, and it is suggested that cancer-derived
EVs are possible mediators between tumor-associated
macrophages and cancer progression.
It had been reported that various factors secreted from
cancer cells including cytokines and chemokines, as well
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as microRNAs in EVs, were involved in differentiation
into M2 macrophages or TAM to promote cancer malig-
nancy [22, 39–43]. To polarize macrophages into the
M2 type, the STAT3 pathway and the Akt-mTOR path-
way are known pathways [44, 45]. Although our data
showed that STAT3 was contained in GC-derived EVs, a
recent report demonstrated that STAT3 protein pack-
aged in EVs was transferred from glioblastoma stem
cells into macrophages to polarize them into the M2
phenotype [36]. The results suggested that EVs from
cancer cells might induce M2 macrophages through the
STAT3 pathway. Yu and coworkers also reported that
CD11b +myeloid precursor cells derived from bone
marrow were stimulated by exosomes from murine
mammary tumor cells and upregulated STAT3 [46]. The
persistent activation of STAT3 mediates tumor-
promoting inflammatory pathways, including nuclear
factor-κB (NF-κB) and interleukin-6 (IL-6)–GP130–
Janus kinase (JAK) pathways [47]. STAT3 is commonly
activated in tumor-infiltrating macrophages [48, 49], and
STAT3 can bind to the promoter of the CD274 gene re-
quired for PD-L1 gene expression in T-cell lymphoma
[38, 50]. Therefore, STAT3 activation might also con-
tribute to inducing PD-L1 in macrophages [51]. On
Western blotting, STAT3 protein could be detected in
EVs purified from not only malignant ascitic fluid, but
also peritoneal washings of cytology-positive GC pa-
tients, while STAT3 could not be found in EVs from
cytology-negative GC patients. These data suggest that
cancer cells that infiltrated into the peritoneal cavity
might secrete EVs containing STAT3 and promote
polarization into M2 macrophages.
However, it should be recognized that STAT3 would
not the only pathway that skews macrophages to M2
Fig. 4 EVs from a high metastatic gastric cancer cell line carry STAT3 protein. a Western blotting for each cell lysate. 20 μg / lane. b Western
blotting for EVs derived from each cell line. 2.5 μg / lane. c Western blotting for M0-GM macrophages treated by each EV. 30 μg / lane. Full-length
blots / gels are presented in Fig. S8, S9 and S10
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type, given that EVs carry multiple proteins and nucleic
acids that affect cell function [52]. According to the re-
view by Chatterjee et al., several microRNAs packaged in
EVs from cancer cells have recently been reported to
regulate this process [53]. For instance, EVs containing
miR-222-3p or miR-940 derived from ovarian cancer
cells induce the M2-like phenotype. Colon cancer cells
secrete EVs enriched in miR-1246 or miR-203, thereby
promoting M2 polarization of macrophages. Several
other EVs-loaded microRNAs, such as miR-let7a, miR-
21, miR-125b-5p, miR-21-2p, miR181d-5p, and miR-503
have also been reported to induce M2-like phenotype in
macrophages. Thus, emerging studies have shown that
tumor cells actually secrete EVs which skew macro-
phages to protumor phenotypes, which is consistent
with our results. On the other hand, it is also suggested
that there are multiple pathways in the process.
It has recently been reported that cancer cells polarize
macrophages into the M2 phenotype in co-culture, and
such phenotype changes make macrophages secrete IL-
Fig. 5 Macrophages were treated with EVs from clinical samples. a Morphology and b surface markers of macrophages stimulated by EVs
contained in malignant ascitic fluid. Upper figures indicate macrophages differentiated from GM-M0, and lower figures indicate macrophages
from M-M0. Scale Bar: 100 μm. c Western blotting for EVs from peritoneal washings of a GC patient with peritoneal nodules and malignant
ascites. EVs from Met-5A and GCIY cells were applied for 1.5 μg, and EVs from clinical samples were applied for 1 μl of EV suspension. Full-length
blots / gels are presented in Fig. S11. d Western blotting for EVs from peritoneal washings of a GC patient without peritoneal dissemination. EVs
from cell lines were applied for 1.0 μg, and EVs from clinical samples were applied for 1.5 μg. Full-length blots / gels are presented in Fig. S12
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6, which promotes peritoneal dissemination [25]. In the
present study, M2-macrophages polarized by EVs also
secreted IL-6 to promote malignancy of cancer cells.
Collectively, the EVs from cancer cells might play crucial
roles in boosting the malignant potentials of GC and in
the promotion of peritoneal dissemination.
In this study, we used CD9, CD 63, and CD 81 as
markers of EVs, but the expression intensities of these
markers differed in each sample. Proteins enriched in EV
are often used as markers include tetraspanins (CD9,
CD63, CD81 and CD82), 14–3-3 proteins, major histocom-
patibility complex molecules and cytosolic proteins such as
heat shock proteins [15]. Although CD9 and CD81 belong
to the most frequently identified EV proteins [54], abun-
dance of CD63 was reported to be variable depending on
the cell types [55]. Recently A comprehensive proteomic
analysis of EVs from large number of human samples was
reported [52]. Among conventional markers, heat shock
cognate 71 kDa protein (HSPA8), heat shock protein HSP
90-beta (HSP90AB1), CD9, and programmed cell death 6-
interacting protein (ALIX) appeared to be the most prom-
inent markers found in human-derived EVs isolated from
cells, tissues, and body fluids. It is necessary to recognize
that the panel of human EV markers are drastically expand-
ing by the progress of the EV research.
This study has potential limitations that need to be
addressed. First, macrophage phenotype was classified by
the M1-M2 paradigm, and it was considered that TAMs
are generally closer to M2-polarized macrophages. How-
ever, macrophages actually show a spectrum of activation
states, rather than such dichotomous phenotypes [56].
Although this study was based on the M1 and M2 classifi-
cation scheme, it was chosen to help simplify the
understanding of the association between EVs and macro-
phages. It should be recognized that macrophages are
plastic and versatile, and the concept of M1-M2 extremes
may not capture their whole spectrum [56–59]. Second,
based on the results of the present study, it was assumed
that the macrophages treated with EVs produced IL-6.
The previous studies demonstrated that the main pro-
ducers of IL-6 are the myeloid cells [60, 61]. However,
autocrine IL-6 in epithelial cancer cells has also been doc-
umented [62, 63]. Thus, cells other than peritoneal macro-
phages may also secrete IL-6 under certain conditions.
Third, common problems in experiments with EVs must
be taken into account. The amount of protein contained
in EVs from some GC patients was too low to be sub-
jected to the analysis, which did not allow, for example,
checking the STAT3 level in all clinical samples. The puri-
fication and concentration process of EVs needs to be im-
proved for further investigations. Finally, although
monocytes isolated from one volunteer were used in this
study, analysis of monocytes from many volunteers would
be ideal for obtaining more meaningful data.
Conclusions
EVs derived from GC cells could induce polarization via
the STAT3 pathway into M2-macrophages, which secrete
IL-6 to promote malignancy of cancer cells. EVs derived
from GC play a role by affecting macrophage phenotypes,
and this may be a part of the underlying mechanism that
forms the intraperitoneal cancer microenvironment.
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